Drugs / ADCV01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04115761 | Jun 2019 → Dec 2026 expected | glioblastoma | Ever Supreme Bio Technology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADCV01 | “ADCV01 is autologous dendritic cells (DCs) stimulated by the patients' own tumor antigens.” NCT04115761 ↗ |
| Modality | Cell therapy | “ADCV01 is autologous dendritic cells (DCs) stimulated by the patients' own tumor antigens.” NCT04115761 ↗ |
| Route | Subcutaneous | “The ADCV01 will be administered to the bilateral subaxillary subcutaneous regional lymph nodes” NCT04115761 ↗ |